Tests light therapy for dry mouth after head and neck cancer radiotherapy
Tests light-based photobiomodulation for dry mouth in adults after head and neck cancer radiotherapy.
Plain-language title generated from the registry record
Registry title: Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study
Key facts
- Where
- Granada, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had head and neck cancer, finished treatment and have long-lasting dry mouth after radiotherapy to the salivary glands.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Head and neck cancer, treatment completed and in complete remission; chronic dry mouth (xerostomia) of grade 3 oral dryness (CTCAE version 5.0)
- Earlier treatment
- Must have had radiotherapy to the parotid, submandibular and/or sublingual salivary glands, finished at least 1 month and at most 36 months ago. No new use of drugs, devices or herbs for dry mouth, or no change in their use for 2 months before joining.
Main reasons for not taking part
- Cancer that has spread (metastases)
- Karnofsky Performance Status score below 60
- Conditions that rule out PBM therapy, such as heart rhythm problems, pacemaker, sensitivity to light, light-sensitizing drugs or pregnancy
- Other illnesses such as diabetes, or taking many medicines
- Withdrawing consent
Read by machine on 12 November 2026.
Where in Spain
- Faculty of Health SciencesGranada, SpainContact: Noelia Galiano-Castillo, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universidad de Granada
- Trial code
- NCT05106608
- Record updated
- 17 September 2026
- Original description
The Photobiomodulation therapy could have positive effects on quality of life and oral health in head and neck cancer survivors post-radiotherapy. The improvement in quality of life will be maintained after a follow-up period.Read full original descriptionShow less
Photobiomodulation Therapy With M-health Tool for the Management of Oral Health and Quality of Life in Head and Neck Cancer Patients: LAXER Study
The Photobiomodulation therapy could have positive effects on quality of life and oral health in head and neck cancer survivors post-radiotherapy. The improvement in quality of life will be maintained after a follow-up period.
Patients will be included in the study if they meet the following inclusion criteria:; men or women aged 18 years or older and were diagnosed with HNC; chronic xerostomia; received RT in the parotid, submandibular and/or sublingual salivary glands; grade 3 oral dryness according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE); medical treatment completed and in complete remission; received medical clearance for participation in this study; at least one month passed since the end of RT to avoid the possible presence of oral mucositis and/or radiodermatitis, which limits adherence to treatment and maximum 36 months; no history of drugs/devices/products (pilocarpine, cevimeline, amifostine, oral devices, humidifiers, or herbs) to prevent or treat xerostomia prior to study inclusion or no change in their use (no change in type or dose) for two months prior to study inclusion; and able to access mobile applications or living with someone who has this ability; The exclusion criteria will be as follows:; patients with metastases; a score <60 on the Karnofsky Performance Status Scale; contraindications to receiving PBM therapy (e.g., cardiac arrhythmias, pacemakers, photosensitivity, drugs with photosensitizing action, and pregnancy); other comorbidities such as diabetes and polypharmacy; and retraction of the declaration of consent.